{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T14:22:02Z","timestamp":1790173322998,"version":"4.1.0"},"reference-count":86,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","nmd-journal.com","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuromuscular Disorders"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.nmd.2023.10.003","type":"journal-article","created":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T22:11:22Z","timestamp":1697062282000},"page":"897-910","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["269th ENMC international workshop: 10 years of clinical trials in Duchenne muscular dystrophy \u2013 What have we learned? 9\u201311 December 2022, Hoofddorp, The Netherlands"],"prefix":"10.1016","volume":"33","author":[{"given":"Karin J.","family":"Naarding","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2795-9898","authenticated-orcid":false,"given":"Georgia","family":"Stimpson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan J.","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Goemans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"McDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenio","family":"Mercuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9102-5232","authenticated-orcid":false,"given":"Francesco","family":"Muntoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Goemans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"McDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenio","family":"Mercuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Muntoni\u202f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan J.","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Bettica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Binks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Duong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Ferreiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Furlong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Guglieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Hendrix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Henricson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Yves","family":"Hogrel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mindy","family":"Leffler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terina","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin J.","family":"Naarding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Niks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Servais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Signorovitch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgia","family":"Stimpson\u202f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Van Ieperen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Vroom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nmd.2023.10.003_bib0001","series-title":"of Myology TREAT-NMD Meeting on physical activity Neuromuscular Disorders 2008","first-page":"894","article-title":"Towards harmonisation of outcome measures for DMD and SMA within TREAT-NMD; Report of three expert workshops: TREAT-NMD\/ENMC Workshop on outcome measures","volume":"18","author":"Mercuri","year":"2008"},{"key":"10.1016\/j.nmd.2023.10.003_bib0002","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1136\/jnnp-2012-303902","article-title":"Long-term benefits and adverse effects of intermittent versus daily glucocorticoids in boys with Duchenne muscular dystrophy","volume":"84","author":"Ricotti","year":"2013","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.nmd.2023.10.003_bib0003","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.nmd.2019.02.002","article-title":"Respiratory and upper limb function as outcome measures in ambulant and non-ambulant subjects with Duchenne muscular dystrophy: a prospective multicentre study","volume":"29","author":"Ricotti","year":"2019","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2023.10.003_bib0004","first-page":"121","article-title":"Improvement of survival in duchenne muscular dystrophy: retrospective analysis of 835 patients","volume":"31","author":"Passamano","year":"2012","journal-title":"Acta Myol"},{"key":"10.1016\/j.nmd.2023.10.003_bib0005","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/humu.22758","article-title":"The TREAT-NMD DMD global database: analysis of more than 7,000 duchenne muscular dystrophy mutations","volume":"36","author":"Bladen","year":"2015","journal-title":"Hum Mutat"},{"key":"10.1016\/j.nmd.2023.10.003_bib0006","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/mus.20586","article-title":"Entries in the Leiden Duchenne muscular dystrophy mutation database: an overview of mutation types and paradoxical cases that confirm the reading-frame rule","volume":"34","author":"Aartsma-Rus","year":"2006","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2023.10.003_bib0007","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/humu.20976","article-title":"Genotype-phenotype analysis in 2,405 patients with a dystrophinopathy using the UMD-DMD database: a model of nationwide knowledgebase","volume":"30","author":"Tuffery-Giraud","year":"2009","journal-title":"Hum Mutat"},{"key":"10.1016\/j.nmd.2023.10.003_bib0008","doi-asserted-by":"crossref","first-page":"2906","DOI":"10.1007\/s12325-022-02117-1","article-title":"Disease progression stages and burden in patients with duchenne muscular dystrophy using administrative claims supplemented by electronic medical records","volume":"39","author":"Iff","year":"2022","journal-title":"Adv Ther"},{"key":"10.1016\/j.nmd.2023.10.003_bib0009","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S1474-4422(18)30024-3","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management","volume":"17","author":"Birnkrant","year":"2018","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.nmd.2023.10.003_bib0010","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1097\/PHM.0b013e3181e72207","article-title":"Duchenne muscular dystrophy: the effect of glucocorticoids on ventilator use and ambulation","volume":"89","author":"Bach","year":"2010","journal-title":"Am J Phys Med Rehabil"},{"key":"10.1016\/j.nmd.2023.10.003_bib0011","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.nmd.2015.07.009","article-title":"Benefits of glucocorticoids in non-ambulant boys\/men with Duchenne muscular dystrophy: a multicentric longitudinal study using the Performance of Upper Limb test","volume":"25","author":"Pane","year":"2015","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2023.10.003_bib0012","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/j.chest.2020.04.043","article-title":"Cardiorespiratory progression over 5 Years and role of corticosteroids in duchenne muscular dystrophy: a single-site retrospective longitudinal study","volume":"158","author":"Trucco","year":"2020","journal-title":"Chest"},{"key":"10.1016\/j.nmd.2023.10.003_bib0013","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13023-021-02158-9","article-title":"Growth pattern trajectories in boys with duchenne muscular dystrophy","volume":"17","author":"Stimpson","year":"2022","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.nmd.2023.10.003_bib0014","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.nmd.2018.09.005","article-title":"Fractures and bone health monitoring in boys with duchenne muscular dystrophy managed within the scottish muscle network","volume":"29","author":"Joseph","year":"2019","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2023.10.003_bib0015","first-page":"2017","article-title":"Interventions to prevent and treat corticosteroid-induced osteoporosis and prevent osteoporotic fractures in Duchenne muscular dystrophy","author":"Bell","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.nmd.2023.10.003_bib0016","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.44178","article-title":"Efficacy and safety of vamorolone in duchenne muscular dystrophy","volume":"5","author":"Mah","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.nmd.2023.10.003_bib0017","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.44178","article-title":"Efficacy and safety of vamorolone in duchenne muscular dystrophy: a 30-month nonrandomized controlled open-label extension trial","volume":"5","author":"Mah","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"Suppl 1","key":"10.1016\/j.nmd.2023.10.003_bib0018","doi-asserted-by":"crossref","first-page":"S70","DOI":"10.1016\/j.nmd.2022.07.119","article-title":"Vamorolone has less impact than daily prednisone or deflazacort on height and body mass index in patients with Duchenne Muscular Dystrophy (DMD)","volume":"32","author":"Ward","year":"2022","journal-title":"Euromuscul Disord"},{"key":"10.1016\/j.nmd.2023.10.003_bib0019","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1080\/14712598.2017.1271872","article-title":"Exon skipping: a first in class strategy for Duchenne muscular dystrophy","volume":"17","author":"Niks","year":"2017","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.nmd.2023.10.003_bib0020","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1002\/ana.23982","article-title":"Eteplirsen for the treatment of duchenne muscular dystrophy","volume":"74","author":"Mendell","year":"2013","journal-title":"Ann Neurol"},{"key":"10.1016\/j.nmd.2023.10.003_bib0021","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/ana.24555","article-title":"Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy","volume":"79","author":"Mendell","year":"2016","journal-title":"Ann Neurol"},{"key":"10.1016\/j.nmd.2023.10.003_bib0022","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1007\/s40265-016-0657-1","article-title":"Eteplirsen: first global approval","volume":"76","author":"Syed","year":"2016","journal-title":"Drugs"},{"key":"10.1016\/j.nmd.2023.10.003_bib0023","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s40265-020-01267-2","article-title":"First Approval","volume":"80","author":"Golodirsen","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.nmd.2023.10.003_bib0024","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1007\/s40265-020-01339-3","article-title":"Viltolarsen: first approval","volume":"80","author":"Dhillon","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.nmd.2023.10.003_bib0025","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1001\/jamaneurol.2020.1264","article-title":"Safety, tolerability, and efficacy of viltolarsen in boys with duchenne muscular dystrophy amenable to exon 53 skipping: a phase 2 randomized clinical trial","volume":"77","author":"Clemens","year":"2020","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.nmd.2023.10.003_bib0026","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s40265-021-01512-2","article-title":"Casimersen: first approval","volume":"81","author":"Shirley","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.nmd.2023.10.003_bib0027","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1002\/mus.24332","article-title":"Ataluren treatment of patients with nonsense mutation dystrophinopathy","volume":"50","author":"Bushby","year":"2014","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2023.10.003_bib0028","unstructured":"Committee for medicinal products for human use (CHMP). Assess Rep Translarna (Ataluren) 2018. https:\/\/www.ema.europa.eu\/en\/documents\/variation-report\/translarna-h-c-2720-p46-0025-epar-assessment-report_en.pdf (accessed July 12, 2021)."},{"key":"10.1016\/j.nmd.2023.10.003_bib0029","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cells9122657","article-title":"The failed clinical story of myostatin inhibitors against duchenne muscular dystrophy: exploring the biology behind the battle","volume":"9","author":"Rybalka","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.nmd.2023.10.003_bib0030","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/S1474-4422(23)00285-5","article-title":"Safety and efficacy of tamoxifen in boys with duchenne muscular dystrophy (TAMDMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"22","author":"Henzi","year":"2023","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.nmd.2023.10.003_bib0031","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.003911","article-title":"Tadalafil treatment delays the onset of cardiomyopathy in dystrophin-deficient hearts","volume":"5","author":"Hammers","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.nmd.2023.10.003_bib0032","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/path.4054","article-title":"Sildenafil reduces respiratory muscle weakness and fibrosis in the mdx mouse model of Duchenne muscular dystrophy","volume":"228","author":"Percival","year":"2012","journal-title":"J Pathol"},{"key":"10.1016\/j.nmd.2023.10.003_bib0033","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1002\/ana.24214","article-title":"Sildenafil does not improve cardiomyopathy in duchenne\/becker muscular dystrophy","volume":"76","author":"Leung","year":"2014","journal-title":"Ann Neurol"},{"key":"10.1016\/j.nmd.2023.10.003_bib0034","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1093\/eurheartj\/ehn406","article-title":"Long-term blinded placebo-controlled study of SNT-MC17\/idebenone in the dystrophin deficient mdx mouse: cardiac protection and improved exercise performance","volume":"30","author":"Buyse","year":"2009","journal-title":"Eur Heart J"},{"key":"10.1016\/j.nmd.2023.10.003_bib0035","doi-asserted-by":"crossref","DOI":"10.1002\/ana.26755","article-title":"Delandistrogene moxeparvovec gene therapy in ambulatory patients (aged \u22654 to <8 years) with duchenne muscular dystrophy: 1-year interim results from study SRP-9001-103 (endeavor)","author":"Zaidman","year":"2023","journal-title":"Ann Neurol"},{"key":"10.1016\/j.nmd.2023.10.003_bib0036","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.nmd.2016.05.016","article-title":"Categorizing natural history trajectories of ambulatory function measured by the 6-minute walk distance in patients with Duchenne muscular dystrophy","volume":"26","author":"Mercuri","year":"2016","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2023.10.003_bib0037","doi-asserted-by":"crossref","first-page":"3001","DOI":"10.3389\/fphar.2021.735912","article-title":"Lessons learned from discontinued clinical developments in duchenne muscular dystrophy","volume":"12","author":"Markati","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.nmd.2023.10.003_bib0038","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.nmd.2022.02.009","article-title":"Real-world and natural history data for drug evaluation in duchenne muscular dystrophy: suitability of the north star ambulatory assessment for comparisons with external controls","volume":"32","author":"Muntoni","year":"2022","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2023.10.003_bib0039","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.1172\/JCI91445","article-title":"Intermittent glucocorticoid steroid dosing enhances muscle repair without eliciting muscle atrophy","volume":"127","author":"Quattrocelli","year":"2017","journal-title":"J Clin Invest"},{"key":"10.1016\/j.nmd.2023.10.003_bib0040","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.132402","article-title":"Pulsed glucocorticoids enhance dystrophic muscle performance through epigenetic-metabolic reprogramming","volume":"4","author":"Quattrocelli","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.nmd.2023.10.003_bib0041","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1056\/NEJM198906153202405","article-title":"Randomized, double-blind six-month trial of prednisone in duchenne's muscular dystrophy","volume":"320","author":"Mendell","year":"1989","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nmd.2023.10.003_bib0042","doi-asserted-by":"crossref","first-page":"4225","DOI":"10.1093\/hmg\/ddv155","article-title":"How much dystrophin is enough: the physiological consequences of different levels of dystrophin in the mdx mouse","volume":"24","author":"Godfrey","year":"2015","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.nmd.2023.10.003_bib0043","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0156696","article-title":"A movement monitor based on magneto-inertial sensors for non-ambulant patients with Duchenne muscular dystrophy: a pilot study in controlled environment","volume":"11","author":"Le Moing","year":"2016","journal-title":"PLOS One"},{"key":"10.1016\/j.nmd.2023.10.003_bib0044","article-title":"Home-based monitor for gait and activity analysis","volume":"2019","author":"Lilien","year":"2019","journal-title":"J Vis Exp"},{"key":"10.1016\/j.nmd.2023.10.003_bib0045","doi-asserted-by":"crossref","first-page":"335","DOI":"10.3233\/JND-210743","article-title":"Stride velocity 95th centile: insights into gaining regulatory qualification of the first wearable-derived digital endpoint for use in duchenne muscular dystrophy trials","volume":"9","author":"Servais","year":"2022","journal-title":"J Neuromuscul Dis"},{"key":"10.1016\/j.nmd.2023.10.003_bib0046","doi-asserted-by":"crossref","DOI":"10.1186\/s13023-021-01956-5","article-title":"Normative data on spontaneous stride velocity, stride length, and walking activity in a non-controlled environment","volume":"16","author":"Poleur","year":"2021","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.nmd.2023.10.003_bib0047","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-023-02459-5","article-title":"First regulatory qualification of a digital endpoint to measure treatment efficacy in Duchenne muscular dystrophy","author":"Servais","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.nmd.2023.10.003_bib0048","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.1007\/s11136-019-02245-2","article-title":"Adapting traditional content validation methods to fit purpose: an example with a novel video assessment and training materials in Duchenne muscular dystrophy (DMD)","volume":"28","author":"White","year":"2019","journal-title":"Qual Life Res"},{"key":"10.1016\/j.nmd.2023.10.003_bib0049","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/mus.27335","article-title":"Reliability and construct validity of the duchenne video assessment","volume":"64","author":"Contesse","year":"2021","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2023.10.003_bib0050","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0266845","article-title":"Development of duchenne video assessment scorecards to evaluate ease of movement among those with duchenne muscular dystrophy","volume":"17","author":"Contesse","year":"2022","journal-title":"PLOS One"},{"key":"10.1016\/j.nmd.2023.10.003_bib0051","doi-asserted-by":"crossref","first-page":"555","DOI":"10.3233\/JND-210767","article-title":"The black box of technological outcome measures: an example in duchenne muscular dystrophy the creative commons attribution-noncommercial license (CC BY-NC 4.0)","volume":"9","author":"Naarding","year":"2022","journal-title":"J Neuromuscul Dis"},{"key":"10.1016\/j.nmd.2023.10.003_bib0052","doi-asserted-by":"crossref","DOI":"10.1016\/j.ppedcard.2023.101639","article-title":"Major Adverse Dystrophinopathy Events (MADE) score as marker of cumulative morbidity and risk for mortality in boys with Duchenne muscular dystrophy","author":"Kaufman","year":"2023","journal-title":"Prog Pediatr Cardiol"},{"key":"10.1016\/j.nmd.2023.10.003_bib0053","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.pediatrneurol.2014.09.014","article-title":"Composite biomarkers for assessing duchenne muscular dystrophy: an initial assessment","volume":"52","author":"Shklyar","year":"2015","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.nmd.2023.10.003_bib0054","first-page":"S69","article-title":"68 Validation of a composite prognostic score for time to loss of ambulation in Duchenne muscular dystrophy","volume":"32","author":"McDonald","year":"2022","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2023.10.003_bib0055","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S2213-2600(14)70100-6","article-title":"Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial","volume":"2","author":"Kerem","year":"2014","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.nmd.2023.10.003_bib0056","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/S0140-6736(17)31611-2","article-title":"Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"McDonald","year":"2017","journal-title":"Lancet N Am Ed"},{"key":"10.1016\/j.nmd.2023.10.003_bib0057","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.nmd.2020.05.002","article-title":"Randomized phase 2 trial and open-label extension of domagrozumab in Duchenne muscular dystrophy","volume":"30","author":"Wagner","year":"2020","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2023.10.003_bib0058","doi-asserted-by":"crossref","first-page":"4421","DOI":"10.1007\/s00415-022-11084-0","article-title":"Quantitative magnetic resonance imaging measures as biomarkers of disease progression in boys with Duchenne muscular dystrophy: a phase 2 trial of domagrozumab","volume":"269","author":"Sherlock","year":"2022","journal-title":"J Neurol"},{"key":"10.1016\/j.nmd.2023.10.003_bib0059","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/0021-9681(76)90044-8","article-title":"The combination of randomized and historical controls in clinical trials","volume":"29","author":"Pocock","year":"1976","journal-title":"J Chron Dis"},{"key":"10.1016\/j.nmd.2023.10.003_bib0060","first-page":"6","article-title":"Sarepta therapeutics announces top-line results for part 1 of study 102 evaluating srp-9001, its investigational gene therapy for the treatment of duchenne muscular dystrophy","author":"Therapeutics","year":"2021","journal-title":"Press Release"},{"key":"10.1016\/j.nmd.2023.10.003_bib0061","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.nmd.2022.02.009","article-title":"Real-world and natural history data for drug evaluation in Duchenne muscular dystrophy: suitability of the North Star Ambulatory Assessment for comparisons with external controls","volume":"32","author":"Muntoni","year":"2022","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2023.10.003_bib0062","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0164684","article-title":"Individualized prediction of changes in 6-minute walk distance for patients with duchenne muscular dystrophy","volume":"11","author":"Goemans","year":"2016","journal-title":"PLOS One"},{"key":"10.1016\/j.nmd.2023.10.003_bib0063","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0232870","article-title":"Prognostic factors for changes in the timed 4-stair climb in patients with Duchenne muscular dystrophy, and implications for measuring drug efficacy: a multi-institutional collaboration","volume":"15","author":"Goemans","year":"2020","journal-title":"PLOS One"},{"key":"10.1016\/j.nmd.2023.10.003_bib0064","first-page":"S69","article-title":"68 Validation of a composite prognostic score for time to loss of ambulation in Duchenne muscular dystrophy","volume":"32","author":"McDonald","year":"2022","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2023.10.003_bib0065","doi-asserted-by":"crossref","first-page":"e1386","DOI":"10.1212\/WNL.0000000000008939","article-title":"MRI vastus lateralis fat fraction predicts loss of ambulation in Duchenne muscular dystrophy","volume":"94","author":"Naarding","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2023.10.003_bib0066","doi-asserted-by":"crossref","first-page":"e1737","DOI":"10.1212\/WNL.0000000000012724","article-title":"Association of elbow flexor mri fat fraction with loss of hand-to-mouth movement in patients with duchenne muscular dystrophy","volume":"97","author":"Naarding","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2023.10.003_bib0067","first-page":"S69","article-title":"67 Development and evaluation of a time to event endpoint for clinical trials in Duchenne muscular dystrophy (DMD)","volume":"32","author":"McDonald","year":"2022","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2023.10.003_bib0068","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1177\/2168479013487541","article-title":"A framework for managing the minimal clinically important difference in clinical trials","volume":"47","author":"Koynova","year":"2013","journal-title":"Ther Innov Regul Sci"},{"key":"10.1016\/j.nmd.2023.10.003_bib0069","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/s00109-003-0484-1","article-title":"Therapeutics for duchenne muscular dystrophy: current approaches and future directions","volume":"82","author":"Bogdanovich","year":"2004","journal-title":"J Mol Med"},{"key":"10.1016\/j.nmd.2023.10.003_bib0070","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S1474-4422(09)70271-6","article-title":"Diagnosis and management of duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management","volume":"9","author":"Bushby","year":"2010","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.nmd.2023.10.003_bib0071","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S1474-4422(18)30024-3","article-title":"Diagnosis and management of duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management","volume":"17","author":"Birnkrant","year":"2018","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.nmd.2023.10.003_bib0072","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/1477-7525-4-79","article-title":"Department of health and human services FDA center for devices and radiological health. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance","volume":"4","year":"2006","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.nmd.2023.10.003_bib0073","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/mus.23905","article-title":"The 6-minute walk test and other clinical endpoints in duchenne muscular dystrophy: reliability, concurrent validity, and minimal clinically important differences from a multicenter study","volume":"48","author":"Mcdonald","year":"2013","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2023.10.003_bib0074","doi-asserted-by":"crossref","first-page":"939","DOI":"10.3233\/JND-210646","article-title":"The minimal clinical important difference (mcid) in annual rate of change of timed function tests in boys with DMD","volume":"8","author":"Duong","year":"2021","journal-title":"J Neuromuscul Dis"},{"key":"10.1016\/j.nmd.2023.10.003_bib0075","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1081\/COPD-200050649","article-title":"Challenges associated with estimating minimal clinically important differences in COPD-the nhlbi perspective","volume":"2","author":"Kiley","year":"2005","journal-title":"COPD J Chronic Obstr Pulm Dis"},{"key":"10.1016\/j.nmd.2023.10.003_bib0076","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/1750-1172-8-160","article-title":"The clinical relevance of outcomes used in late-onset Pompe disease: can we do better?","volume":"8","author":"Lachmann","year":"2013","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.nmd.2023.10.003_bib0077","doi-asserted-by":"crossref","first-page":"176","DOI":"10.2522\/ptj.20070064","article-title":"Measuring deterioration in international classification of functioning domains of people with multiple sclerosis who are ambulatory","volume":"88","author":"Paltamaa","year":"2008","journal-title":"Phys Ther"},{"key":"10.1016\/j.nmd.2023.10.003_bib0078","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0140-6736(17)32160-8","article-title":"Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort study","volume":"391","author":"McDonald","year":"2018","journal-title":"Lancet N. Am Ed"},{"key":"10.1016\/j.nmd.2023.10.003_bib0079","article-title":"The 6-minute walk test and person-reported outcomes in boys with duchenne muscular dystrophy and typically developing controls: longitudinal comparisons and clinically-meaningful changes over one year","volume":"5","author":"Henricson","year":"2013","journal-title":"PLOS Curr"},{"key":"10.1016\/j.nmd.2023.10.003_bib0080","doi-asserted-by":"crossref","first-page":"S66","DOI":"10.1016\/j.nmd.2022.07.103","article-title":"55 A concisely recorded ambulatory assessment for enhancing real-world outcomes research in Duchenne muscular dystrophy: development and validation","volume":"32","author":"Mayhew","year":"2022","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2023.10.003_bib0081","unstructured":"A Collaborative Analysis by Clinical Trial Sponsors and Academic Experts of Anti-transgene SAEs in Studies of Gene Therapy for DMD-Web of Science Core Collection. In Muscular Dystrophy Association 2023 conference, Conference, 19-23 Mar 2023. Abstract 2023 https:\/\/www.webofscience.com\/wos\/woscc\/full-record\/WOS:000800390700006?SID=EUW1ED0F50A54sjWBr7ElzqaMrHLl (accessed May 3, 2023)."},{"key":"10.1016\/j.nmd.2023.10.003_bib0082","doi-asserted-by":"crossref","first-page":"e1540","DOI":"10.1212\/WNL.0000000000201626","article-title":"DMD genotypes and motor function in duchenne muscular dystrophy","volume":"100","author":"Muntoni","year":"2023","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2023.10.003_bib0083","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1212\/WNL.0000000000004570","article-title":"A phase 3 randomized placebo-controlled trial of tadalafil for duchenne muscular dystrophy","volume":"89","author":"Victor","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2023.10.003_bib0084","first-page":"1","article-title":"Effect of different corticosteroid dosing regimens on clinical outcomes in boys with duchenne muscular dystrophy","author":"Guglieri","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.nmd.2023.10.003_bib0085","doi-asserted-by":"crossref","first-page":"433","DOI":"10.3233\/JND-200541","article-title":"Decision-making and selection bias in four observational studies on duchenne and becker muscular dystrophy the creative commons attribution non-commercial license (CC BY-NC 4.0)","volume":"7","author":"Naarding","year":"2020","journal-title":"J Neuromuscul Dis"},{"key":"10.1016\/j.nmd.2023.10.003_bib0086","article-title":"Disease progression rates in ambulatory Duchenne muscular dystrophy by steroid type, patient age and functional status","volume":"12","author":"McDonald","year":"2023","journal-title":"J Comp Eff Res"}],"container-title":["Neuromuscular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896623007484?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896623007484?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T22:41:18Z","timestamp":1717540878000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960896623007484"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":86,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S0960896623007484"],"URL":"https:\/\/doi.org\/10.1016\/j.nmd.2023.10.003","relation":{},"ISSN":["0960-8966"],"issn-type":[{"value":"0960-8966","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"269th ENMC international workshop: 10 years of clinical trials in Duchenne muscular dystrophy \u2013 What have we learned? 9\u201311 December 2022, Hoofddorp, The Netherlands","name":"articletitle","label":"Article Title"},{"value":"Neuromuscular Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nmd.2023.10.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"name":"copyright","label":"Copyright"}]}}